Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.87
-$0.04(-0.79%)
At close: 4:00 PM EST
$1.87
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.54 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)1.19M
Market Cap
$74.45M
Enterprise Value$20.01M
Total Cash (Recent Filing)$14.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 18, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding42,541,866
10 Day Avg. Volume982,612
30 Day Avg. Volume1,187,671
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$12.50Price Target Upside568.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Reported DebtA zero-debt balance sheet materially reduces default and interest-rate risk and gives management flexibility to prioritize R&D spending. For a clinical-stage biotech, no scheduled interest burdens extends runway capacity and lowers fixed-cost pressure while pursuing lengthy Phase 3 programs.
Lead Asset In Phase 3 (buntanetap)Advancing buntanetap into Phase 3 represents a structural de-risking step versus earlier-stage candidates. A Phase 3 program creates clearer regulatory and commercial decision points, increases partnering or licensing optionality, and concentrates value creation around a near-term clinical readout.
Proven Access To Capital MarketsSuccessful registered-direct and public offerings demonstrate persistent investor willingness to finance the pipeline, providing near-term funding to run pivotal trials. Structural access to equity markets reduces immediate liquidity risk and supports execution of multi-year clinical programs.
Bears Say
No Product RevenueZero revenue is a durable structural constraint: the firm must rely entirely on external funding until a product is commercialized or licensed. This absence of operating income amplifies execution risk and places long-term sustainability on successful trial outcomes or continued capital raises.
Persistent Negative Operating And Free Cash FlowConsistently negative operating and free cash flows indicate ongoing cash consumption to fund trials, shortening runway without new financing. The worsening and volatile cash-burn profile makes planning and milestone funding uncertain and increases the probability of future dilutive financings.
Reliance On Dilutive Equity FinancingsFrequent, sizable equity issuances to fund trials structurally dilute existing shareholders and signal sustained dependence on markets rather than internal cash generation. This reliance can pressure long-term returns and complicate per-share economics if commercial success is delayed or outcomes miss expectations.
Annovis Bio News
ANVS FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was $1.54 and its highest was $5.50 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is $74.45M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is Aug 18, 2026 which is in 48 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on May 15, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.235.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.46.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 42,541,866 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -3.286%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (568.45% Upside)
$12.50 (568.45% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.28%
12-Months-Change
Fundamentals
Return on Equity
-318.08%
Trailing 12-Months
Asset Growth
-39.25%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.50
▲(568.45% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
11.32% Insiders
2.59% Mutual Funds
0.96% Other Institutional Investors
81.42% Public Companies and
Individual Investors